On January 4, 2018 ActoBio Therapeutics, Inc., a wholly owned subsidiary of Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, reported that Pieter Rottiers, PhD, ActoBio’s Chief Executive Officer, will present at the Biotech Showcase 2018 Conference in San Francisco on Monday, January 8th at 2 p.m. Pacific Time (Press release, Intrexon, JAN 4, 2018, View Source [SID1234522881]). The presentation will highlight the innovative, proprietary ActoBiotics drug delivery platform for oral and topical administration of biologicals to address unmet medical needs for diverse health indications.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
ActoBio Therapeutics combines world-class science, preclinical and clinical-stage products, and a leadership team with over 20 years hands-on experience developing the platform. ActoBio has reached a significant level of development and is well prepared to move forward to create significant new therapeutic modalities across a broad set of markets with strong growth dynamics including oral, gastrointestinal, and autoimmune/allergic disorders. Using the innovative ActoBiotics platform, we have built a strong R&D pipeline with the latest stage therapeutic candidate in Phase 2b and an extensive portfolio of candidates both partnered and self-owned ready for clinical development across a number of conditions," Dr. Rottiers commented.
A live webcast of the presentation will be available on the Investors section of Intrexon’s website at View Source Replay of the webcast will be available for 30 days following the event.